Allogene Therapeutics
Bernadette D. has an extensive background in biotechnology and pharmaceuticals, holding leadership and scientific roles across various companies. At Allogene Therapeutics, Bernadette D. serves as Associate Director, while previously at TrueBinding (formerly Immutics), Bernadette D. was a Principal Scientist. Bernadette D. also worked as a Principal Engineer at Adicet Bio, Inc., and held the position of Associate Director at BIONOVA SCIENTIFIC LLC. Early career experiences include roles as Scientist II and Associate Scientist at Boehringer Ingelheim.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.